复方红豆杉胶囊联合顺铂方案治疗非小细胞肺癌临床观察
|
摘要
目的:探究复方红豆杉胶囊联合顺铂方案对非小细胞肺癌的作用效果。方法:选取2015年11月至2017年5月解放军总医院中医院收治的非小细胞肺癌患者76例作为研究对象,采用随机数字表法随机分为观察组和对照组,每组38例。对照组患者给予常规化疗方案,观察组患者在对照组的基础上加用复方红豆杉胶囊,对2组患者的癌灶面积、Karnofsky评分、肿瘤标记物及临床有效率进行评价。结果:治疗后,观察组和对照组治疗有效率分别为89.47%、78.95%,观察组治疗有效率显著高于对照组,差异有统计学意义(P<0.05);2组患者治疗后癌灶面积较治疗前明显缩小,且观察组癌灶缩小面积显著大于对照组,差异有统计学意义(P<0.05);Karnofsky评分显示,治疗后2组患者评分均高于治疗前,且观察组评分增加较对照组更为显著,差异有统计学意义(P<0.05);治疗后,2组患者肿瘤标记物水平较治疗前明显降低(P<0.05),但组间比较差异无统计学意义(P>0.05)。结论:临床上使用复方红豆杉胶囊对肺癌患者进行治疗具有提高治疗有效率、缩小癌灶面积、改善患者生命质量的显著作用,有助于提高肺癌的治疗水平,可将该方法作为主要的治疗手段在临床上推广应用。
Objective: To investigate the effect of compound taxus capsules combined with cisplatin on non-small cell lung cancer.Methods: A total of 76 cases came to our department from November 2015 to May 2017 and diagnosed with non-small cell lung cancer werechoosed. They randomly divided into observation group and control group,each group of 38 cases. The control group was treated with conventional chemotherapy regimens,and the observation group added the compound hongyew capsule. Evaluate the focal area,Karnofsky score,tumor marker and clinical efficiency of the two groups. Results: After treatment,the treatment efficiency of observation group and control group were 89. 47% and 78. 95% respectively. And the treatment efficiency of the observation group was significantly higher than that in the control group( P < 0. 05). The area of cancer focal area was significantly smaller than that of the treatment group in both two groups,and the reduction area of cancer focal area was significantly larger than that in the control group( P < 0. 05). After treatment,the Karnofsky scores were higher than those before treatment in both two groups,and the observation group score increased significantly compared with the control group( P < 0. 05). After treatment,the level of tumor markers in both groups decreased significantly( P < 0. 05),but there was no statistical difference between the two groups( P> 0. 05). Conclusion: The compound yew capsule can significantly improve the treatment efficiency,reduce the tumor area and improve the quality of life of the patients. It is helpful to promote the treatment of lung cancer,and can be used as the main therapeutic method in clinic.
Objective: To investigate the effect of compound taxus capsules combined with cisplatin on non-small cell lung cancer.Methods: A total of 76 cases came to our department from November 2015 to May 2017 and diagnosed with non-small cell lung cancer werechoosed. They randomly divided into observation group and control group,each group of 38 cases. The control group was treated with conventional chemotherapy regimens,and the observation group added the compound hongyew capsule. Evaluate the focal area,Karnofsky score,tumor marker and clinical efficiency of the two groups. Results: After treatment,the treatment efficiency of observation group and control group were 89. 47% and 78. 95% respectively. And the treatment efficiency of the observation group was significantly higher than that in the control group( P < 0. 05). The area of cancer focal area was significantly smaller than that of the treatment group in both two groups,and the reduction area of cancer focal area was significantly larger than that in the control group( P < 0. 05). After treatment,the Karnofsky scores were higher than those before treatment in both two groups,and the observation group score increased significantly compared with the control group( P < 0. 05). After treatment,the level of tumor markers in both groups decreased significantly( P < 0. 05),but there was no statistical difference between the two groups( P> 0. 05). Conclusion: The compound yew capsule can significantly improve the treatment efficiency,reduce the tumor area and improve the quality of life of the patients. It is helpful to promote the treatment of lung cancer,and can be used as the main therapeutic method in clinic.
引文
[1]Sullivan I,Planchard D.Targeting ALK-rearranged non-small-cell lung cancer:an update[J].Future Oncol,2017,13(14):1213-1217.
[2]姚晓军,刘伦旭.肺癌的流行病学及治疗现状[J].现代肿瘤医学,2014,22(8):1982-1986.
[3]孟凡谋.复方红豆杉胶囊治疗肝癌临床研究[J].亚太传统医药,2016,12(16):145-146.
[4]国家食品药品监督管理局.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002.
[5]汤晓梅,易向军.同步放化疗联合复方红豆杉胶囊治疗局部晚期肺癌的临床研究[J].当代医学,2016,22(17):17-18.
[6]张晓炜.复方红豆杉胶囊联合TP方案治疗中晚期非小细胞肺癌的疗效观察[J].陕西中医,2015,36(7):833-835.
[7]李力更,霍长虹,董玫,等.美丽红豆杉树皮中化学成分的研究[J].中草药,2010,41(3):355-361.
[8]刘丹,濮社班,钱士辉,等.中国红参化学成分的研究[J].中国中药杂志,2011,36(4):462-464.
[9]许海顺,蒋剑平,徐攀,等.红参多糖抗氧化活性的研究[J].浙江中医药大学学报,2011,35(6):909-912.
[10]王久粉,刘丹,钱士辉,等.中国红参化学成分的研究(Ⅱ)[J].中国野生植物资源,2011,30(6):55-56,59.
[11]张明发,沈雅琴.甘草及其活性成分抗炎与抗炎机制的研究进展[J].现代药物与临床,2011,26(4):261-268.
[12]张明发,沈雅琴.甘草粗提物及其黄酮类成分的抗肿瘤作用[J].现代药物与临床,2010,25(2):124-129.
[13]王晓静,钱彦方,姬广辉,等.复方红豆杉胶囊配合夏凌养阴方治疗肺癌临床观察[J].中医学报,2014,29(4):478-479.
[14]王海明,任芳.复方红豆杉胶囊治疗老年中晚期肺癌24例临床观察[J].科学技术与工程,2014,14(6):90-92.
[2]姚晓军,刘伦旭.肺癌的流行病学及治疗现状[J].现代肿瘤医学,2014,22(8):1982-1986.
[3]孟凡谋.复方红豆杉胶囊治疗肝癌临床研究[J].亚太传统医药,2016,12(16):145-146.
[4]国家食品药品监督管理局.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002.
[5]汤晓梅,易向军.同步放化疗联合复方红豆杉胶囊治疗局部晚期肺癌的临床研究[J].当代医学,2016,22(17):17-18.
[6]张晓炜.复方红豆杉胶囊联合TP方案治疗中晚期非小细胞肺癌的疗效观察[J].陕西中医,2015,36(7):833-835.
[7]李力更,霍长虹,董玫,等.美丽红豆杉树皮中化学成分的研究[J].中草药,2010,41(3):355-361.
[8]刘丹,濮社班,钱士辉,等.中国红参化学成分的研究[J].中国中药杂志,2011,36(4):462-464.
[9]许海顺,蒋剑平,徐攀,等.红参多糖抗氧化活性的研究[J].浙江中医药大学学报,2011,35(6):909-912.
[10]王久粉,刘丹,钱士辉,等.中国红参化学成分的研究(Ⅱ)[J].中国野生植物资源,2011,30(6):55-56,59.
[11]张明发,沈雅琴.甘草及其活性成分抗炎与抗炎机制的研究进展[J].现代药物与临床,2011,26(4):261-268.
[12]张明发,沈雅琴.甘草粗提物及其黄酮类成分的抗肿瘤作用[J].现代药物与临床,2010,25(2):124-129.
[13]王晓静,钱彦方,姬广辉,等.复方红豆杉胶囊配合夏凌养阴方治疗肺癌临床观察[J].中医学报,2014,29(4):478-479.
[14]王海明,任芳.复方红豆杉胶囊治疗老年中晚期肺癌24例临床观察[J].科学技术与工程,2014,14(6):90-92.